FDA approves first drug for aggressive multiple sclerosis
U.S. regulators have approved the first drug for an aggressive kind of multiple sclerosis that steadily reduces coordination and the ability to walk.
Mar 29, 2017
0
28
U.S. regulators have approved the first drug for an aggressive kind of multiple sclerosis that steadily reduces coordination and the ability to walk.
Mar 29, 2017
0
28
Doctors seeking a cure for an aggressive form of multiple sclerosis keep chasing a mirage: no matter how well a drug works in the lab, it never seems to help many patients in the clinic. But after closely examining stem cells ...
Mar 29, 2017
0
80
A new paper published in the Annals of Neurology reports the most common neurological diseases pose a serious annual financial burden for the nation.
Mar 28, 2017
0
1
A person carrying variants of two particular genes could be almost three times more likely to develop multiple sclerosis, according to the latest findings from scientists at The University of Texas Medical Branch at Galveston ...
Mar 23, 2017
0
57
A new, non-invasive test developed by researchers at the University of Georgia shows how exercise can help people with neurological injuries and illnesses.
Mar 9, 2017
0
0
Opening up narrowed veins from the brain and spinal cord is not effective in treating multiple sclerosis (MS), according to a study led by the University of British Columbia and Vancouver Coastal Health.
Mar 8, 2017
0
2
Physical activities incorporating horseback riding can help to improve strength, balance, and other outcomes for children and adults with a range of neuromotor, developmental, and physical disabilities, according to a report ...
Mar 2, 2017
0
2
(HealthDay)—Multiple sclerosis (MS) is more likely to progress to advanced disease among patients who suffer from fatigue and limited use of their legs, new research suggests.
Mar 1, 2017
0
80
Patients with multiple sclerosis had better problem solving ability and response time after training with a technology called transcranial direct current stimulation (tDCS), according to a new study published February 22, ...
Feb 22, 2017
0
6
Results from a new Phase 3 study conducted by the Celgene Corporation demonstrate that ozanimod, a drug candidate originally discovered and optimized at The Scripps Research Institute (TSRI), can reduce the frequency of multiple ...
Feb 21, 2017
0
2